Dynavax Technologies Corporation (DVAX)

Market Cap	1.70B
Revenue (ttm)	277.25M
Net Income (ttm)	27.31M
Shares Out	124.07M
EPS (ttm)	0.20
PE Ratio	68.40
Forward PE	40.84
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,344,803
Open	13.72
Previous Close	13.72
Day's Range	13.53 - 13.77
52-Week Range	9.74 - 14.63
Beta	1.23
Analysts	Hold
Price Target	25.33 (+85.16%)
Earnings Date	May 7, 2025

About DVAX

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the pr...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 19, 2004
• Employees: 405
• Stock Exchange: NASDAQ
• Ticker Symbol: DVAX
• Website: https://www.dynavax.com

Analyst Forecast

According to 3 analysts, the average rating for DVAX stock is "Hold." The 12-month stock price forecast is $25.33, which is an increase of 85.16% from the latest price.

Price Target

$25.33

(85.16% upside)

Analyst Consensus: Hold